Converting Basal-Bolus to Mixtard on Discharge

Critical Evidence Against Mixtard Conversion

The American Diabetes Association recommends against converting to Mixtard due to significantly higher hypoglycemia rates and inferior glycemic control compared to continuing basal-bolus therapy in patients with type 2 diabetes 1, 2
Randomized trials demonstrate that premixed insulin regimens, like Mixtard, have unacceptably high rates of iatrogenic hypoglycemia in hospital settings and should be avoided 3
Basal-bolus therapy provides better glycemic control with reduced hospital complications compared to premixed insulin regimens 3
Premixed insulin has significantly increased hypoglycemia rates 3
Guidelines explicitly recommend against using premixed insulin in hospitalized patients 3

For patients with HbA1c <7.5-8%, the American College of Endocrinology recommends resuming the patient's prehospitalization treatment regimen, including oral agents and/or insulin, at the doses used in the hospital 1, 2
For Type 1 diabetes, the Endocrine Society recommends continuing basal-bolus insulin at hospital doses 1, 2, 6
For Type 2 diabetes, the American Diabetes Association recommends transitioning back to oral agents plus basal insulin at 50% of the hospital basal dose 4, 5
The European Association for the Study of Diabetes recommends scheduling follow-up with the treating physician at one month 1, 2, 6

The American College of Endocrinology recommends calculating the total daily insulin dose from the current basal-bolus regimen and reducing it by 20% to prevent hypoglycemia 3
The total daily insulin dose should be split, with 2/3 of the total dose given before breakfast and 1/3 given before dinner 3

The American Diabetes Association recommends never abruptly discontinuing oral medications when converting insulin regimens due to the risk of rebound hyperglycemia 4, 5
The Endocrine Society recommends never using Mixtard in Type 1 diabetes patients, as they require basal-bolus insulin with separate basal and prandial components for physiologic replacement 1, 2, 6
The American Geriatrics Society recommends avoiding Mixtard in elderly patients (>65 years) with multiple comorbidities 5, 7
The National Kidney Foundation recommends avoiding Mixtard in patients with renal impairment 3

The American Association of Clinical Endocrinologists recommends rechecking HbA1c in 3 months 8
The American Diabetes Association recommends providing clear hypoglycemia recognition and treatment education 4, 5

The European Association for the Study of Diabetes recommends transitioning to basal insulin alone, plus oral agents, for Type 2 diabetes patients who need simplification 4, 5
The American College of Endocrinology recommends starting with 50% of the hospital basal dose and continuing metformin 4, 5
The American Diabetes Association recommends considering adding a DPP-4 inhibitor or GLP-1 RA 4, 5